Liquidia Corporation Common Stock (LQDA) is a publicly traded Healthcare sector company. As of May 21, 2026, LQDA trades at $60.88 with a market cap of $5.07B and a P/E ratio of 254.58. LQDA moved +2.94% today. Year to date, LQDA is +92.13%; over the trailing twelve months it is +262.93%. Its 52-week range spans $9.71 to $62.17. Analyst consensus is strong buy with an average price target of $64.83. Rallies surfaces LQDA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Liquidia Sees 60% Q1 Revenue Surge to $18.4M, Expands Facility 40%: Liquidia posted Q1 2026 revenue of $18.4 million, up 60% year-over-year, driven by increased Yutrepia prescriptions and license fees. The company also announced a 40% capacity expansion at its Morrisville facility and advanced its LIQ861 pulmonary pipeline into Phase 3 enrollment.
| Metric | Value |
|---|---|
| Price | $60.88 |
| Market Cap | $5.07B |
| P/E Ratio | 254.58 |
| EPS | $0.24 |
| Dividend Yield | 0.00% |
| 52-Week High | $62.17 |
| 52-Week Low | $9.71 |
| Volume | 1.53M |
| Avg Volume | 0 |
| Revenue (TTM) | $288.06M |
| Net Income | $22.30M |
| Gross Margin | 0.00% |
7 analysts cover LQDA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $64.83.